文献速递心脑血管急症

西罗莫司洗脱生物可吸收聚合物支架(MiStent)与依维莫司洗脱耐久聚合物支架(Xience)在经皮冠状动脉介入治疗后的比较(DESSOLVE III):一项随机、单盲、多中心、非劣效性3期试验

A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
PubMed 文献 · Lancet · 2017-12-05
一句话结论在全体人群(all-comer)中,MiStent西罗莫司洗脱生物可吸收聚合物支架在12个月器械导向复合终点上非劣于Xience依维莫司洗脱耐久聚合物支架。

DESSOLVE III是一项在德国、法国、荷兰和波兰20家医院开展的随机、单盲、多中心、非劣效性3期试验,纳入≥18岁接受经皮冠状动脉介入治疗且参考血管直径2.50-3.75 mm的患者,1:1随机接受MiStent西罗莫司洗脱生物可吸收聚合物支架或Xience依维莫司洗脱耐久聚合物支架。共随机1398例患者(2030处病变),MiStent组703例(1037处病变),Xience组695例(993处病变)。12个月主要终点(器械导向复合终点:心源性死亡、靶血管心肌梗死或临床指示的靶病变血运重建)MiStent组40例(5.8%)vs Xience组45例(6.5%),绝对差异-0.8%(95%CI -3.3至1.8),非劣效性p=0.0001,非劣效界值4.0%。支架血栓发生率两组无差异且均较低。作者认为MiStent似乎是临床实践中其他支架的合理替代选择。

要点

  • 全体人群(all-comer)中,MiStent组12个月器械导向复合终点5.8%(40/703)vs Xience组6.5%(45/695),绝对差异-0.8%(95%CI -3.3至1.8),非劣效性p=0.0001。
  • 非劣效界值预设为4.0%,MiStent组与Xience组比较达到非劣效。
  • 操作并发症MiStent组12例(1.7%)vs Xience组10例(1.4%),随访至少12个月内未发现与支架脱载相关的临床不良事件。
  • 支架血栓(安全性指标)发生率两组无差异且均较低。
  • 作者认为MiStent似乎是临床实践中其他支架的合理替代选择。

适用人群与场景

  • 年龄至少18岁、接受经皮冠状动脉介入治疗且参考血管直径2.50-3.75 mm的患者(全体人群,all-comer)。

诊断标准与关键阈值

  • 非劣效性界值:MiStent组与Xience组比较的器械导向复合终点非劣效界值为4.0%。

研究设计与关键结果

  • 研究类型:随机、单盲、多中心、非劣效性3期试验,在德国、法国、荷兰和波兰20家医院开展。
  • 样本量:随机1398例患者(2030处病变);MiStent组703例(1037处病变),其中697例接受索引操作;Xience组695例(993处病变),其中690例接受索引操作。
  • 干预与对照:1:1随机接受MiStent西罗莫司洗脱生物可吸收聚合物支架或Xience依维莫司洗脱耐久聚合物支架植入。
  • 主要终点(12个月器械导向复合终点,意向性治疗分析):MiStent组40例(5.8%)vs Xience组45例(6.5%),绝对差异-0.8%(95%CI -3.3至1.8),非劣效性p=0.0001。
  • 操作并发症:MiStent组12例(1.7%)vs Xience组10例(1.4%);随访至少12个月内未发现与支架脱载相关的临床不良事件。
  • 支架血栓发生率两组无差异且均较低。

证据类型、等级与局限

  • 证据类型:随机、单盲、多中心、非劣效性3期试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在全体人群(all-comer)中,MiStent西罗莫司洗脱生物可吸收聚合物支架在12个月器械导向复合终点上非劣于Xience依维莫司洗脱耐久聚合物支架,作者认为MiStent似乎是临床实践中其他支架的合理替代选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: MiStent is a drug-eluting stent with a fully absorbable polymer coating containing and embedding a microcrystalline form of sirolimus into the vessel wall. It was developed to overcome the limitation of current durable polymer drug-eluting stents eluting amorphous sirolimus. The clinical effect of MiStent sirolimus-eluting stent compared with a durable polymer drug-eluting stents has not been investigated in a large randomised trial in an all-comer population.

METHODS: We did a randomised, single-blind, multicentre, phase 3 study (DESSOLVE III) at 20 hospitals in Germany, France, Netherlands, and Poland. Eligible participants were any patients aged at least 18 years who underwent percutaneous coronary intervention in a lesion and had a reference vessel diameter of 2·50-3·75 mm. We randomly assigned patients (1:1) to implantation of either a sirolimus-eluting bioresorbable polymer stent (MiStent) or an everolimus-eluting durable polymer stent (Xience). Randomisation was done by local investigators via web-based software with random blocks according to centre. The primary endpoint was a non-inferiority comparison of a device-oriented composite endpoint (DOCE)-cardiac death, target-vessel myocardial infarction, or clinically indicated target lesion revascularisation-between the groups at 12 months after the procedure assessed by intention-to-treat. A margin of 4·0% was defined for non-inferiority of the MiStent group compared with the Xience group. All participants were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT02385279.

FINDINGS: Between March 20, and Dec 3, 2015, we randomly assigned 1398 patients with 2030 lesions; 703 patients with 1037 lesions were assigned to MiStent, of whom 697 received the index procedure, and 695 patients with 993 lesions were asssigned to Xience, of whom 690 received the index procedure. At 12 months, the primary endpoint had occurred in 40 patients (5·8%) in the sirolimus-eluting stent group and in 45 patients (6·5%) in the everolimus-eluting stent group (absolute difference -0·8% [95% CI -3·3 to 1·8], pnon-inferiority=0·0001). Procedural complications occurred in 12 patients (1·7%) in the sirolimus-eluting stent group and ten patients (1·4%) in the everolimus-eluting stent group; no clinical adverse events could be attributed to these dislodgements through a minimum of 12 months of follow-up. The rate of stent thrombosis, a safety indicator, did not differ between groups and was low in both treatment groups.

INTERPRETATION: The sirolimus-eluting bioabsorbable polymer stent was non-inferior to the everolimus-eluting durable polymer stent for a device-oriented composite clinical endpoint at 12 months in an all-comer population. MiStent seems a reasonable alternative to other stents in clinical practice.

FUNDING: The European Cardiovascular Research Institute, Micell Technologies (Durham, NC, USA), and Stentys (Paris, France).

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. de Winter RJ, Katagiri Y, Asano T, et al. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. Lancet. 2017. PMID: 29203070. doi:10.1016/S0140-6736(17)33103-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。